List of Excipients in Branded Drug AMVUTTRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alnylam Pharmaceuticals Inc	AMVUTTRA	vutrisiran	71336-1003	PHOSPHORIC ACID	2032-03-20
Alnylam Pharmaceuticals Inc	AMVUTTRA	vutrisiran	71336-1003	SODIUM CHLORIDE	2032-03-20
Alnylam Pharmaceuticals Inc	AMVUTTRA	vutrisiran	71336-1003	SODIUM HYDROXIDE	2032-03-20
Alnylam Pharmaceuticals Inc	AMVUTTRA	vutrisiran	71336-1003	SODIUM PHOSPHATE, DIBASIC, DIHYDRATE	2032-03-20
Alnylam Pharmaceuticals Inc	AMVUTTRA	vutrisiran	71336-1003	SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE	2032-03-20
Alnylam Pharmaceuticals Inc	AMVUTTRA	vutrisiran	71336-1003	WATER	2032-03-20

Amvuttra Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Amvuttra (vutrisiran) uses a low-complexity, preservative-free aqueous formulation delivered by a prefilled syringe once every three months. Its commercial value is driven less by excipient novelty than by the integration of a GalNAc-conjugated siRNA, a concentrated liquid formulation, a stable parenteral presentation, and a low-frequency dosing schedule. The strongest opportunities are in excipient quality systems, syringe and device compatibility, cold-chain optimization, analytical control, and follow-on oligonucleotide formulations.

What is the Amvuttra formulation and which excipients does it contain?

Amvuttra is a sterile solution for subcutaneous injection containing 25 mg of vutrisiran in a 0.5 mL prefilled syringe. The formulation uses sodium phosphate dibasic, sodium chloride, polysorbate 20, and Water for Injection as inactive ingredients. The product has a target pH of approximately 7.0 and is supplied without a preservative. (U.S. Food and Drug Administration [FDA], 2024a)

Formulation attribute	Amvuttra profile
Active ingredient	Vutrisiran
Drug class	GalNAc-conjugated small interfering RNA
Route	Subcutaneous injection
Presentation	Single-dose prefilled syringe
Dose	25 mg
Fill volume	0.5 mL
Dosing interval	Once every three months
Buffer	Sodium phosphate dibasic
Tonicity agent	Sodium chloride
Surfactant	Polysorbate 20
Vehicle	Water for Injection
Preservative	None
Storage	Refrigerated storage; product labeling controls light exposure, freezing and agitation

The formulation is materially different from lipid nanoparticle siRNA products such as Onpattro. Vutrisiran uses a triantennary N-acetylgalactosamine, or GalNAc, ligand to target hepatocytes through the asialoglycoprotein receptor. It therefore does not require the ionizable lipid, helper lipid, cholesterol and polyethylene glycol-lipid system used in lipid nanoparticle delivery. (Alnylam Pharmaceuticals, 2024a; Nair et al., 2014)

Why does Amvuttra use a simple excipient system?

The excipient system supports three primary requirements: oligonucleotide stability, subcutaneous tolerability and compatibility with a low-volume prefilled syringe.

Sodium phosphate dibasic provides pH control. Maintaining a near-neutral pH helps limit chemical degradation and supports injection-site tolerability. Sodium chloride adjusts osmolality, reducing the risk of pain or tissue irritation after subcutaneous administration.

Polysorbate 20 is the principal interfacial stabilizer. It can reduce adsorption of the siRNA conjugate to glass, elastomeric components, stainless steel manufacturing equipment and syringe surfaces. It also limits aggregation caused by air-liquid interfaces during filling, transport and handling.

Water for Injection provides the aqueous vehicle. The absence of a preservative is consistent with the single-dose, prefilled-syringe presentation and reduces the number of formulation variables that must be managed for a chronic injectable product.

The strategy has commercial advantages:

• Fewer excipients simplify regulatory qualification.
• A low excipient burden reduces the risk of incompatibility with the siRNA conjugate.
• A preservative-free presentation supports single-use administration.
• The 0.5 mL fill volume is compatible with subcutaneous injection and a compact prefilled-syringe device.
• The formulation avoids the manufacturing and analytical complexity of lipid nanoparticles.

The strategy also creates quality risks. Polysorbate 20 can undergo hydrolysis and oxidation, potentially generating subvisible particles or affecting protein and oligonucleotide stability. Although vutrisiran is not a protein, the same surfactant degradation mechanisms remain relevant to injectable product quality. Container closure, headspace oxygen, light exposure, agitation and temperature excursions require control.

What commercial opportunities exist in Amvuttra excipients?

The largest opportunities are in supply reliability, formulation analytics and delivery components rather than the sale of commodity excipients alone.

High-value excipient opportunities

Opportunity	Commercial rationale	Entry barrier
Pharmaceutical-grade polysorbate 20	Requires low peroxide, low aldehyde and controlled particulate profiles	Moderate
Excipient characterization	Supports oxidation, hydrolysis, particle and impurity testing	Moderate
Excipient supply qualification	Dual sourcing can reduce manufacturing disruption	High
Prefilled-syringe compatibility	Controls adsorption, silicone oil, extractables and leachables	High
Cold-chain services	Supports refrigerated storage and excursion management	Moderate
Oligonucleotide formulation development	Applies Amvuttra-type design to next-generation siRNA products	High
Sterile fill-finish	Low-volume, single-dose syringe filling requires specialized lines	High
Stability-indicating methods	Required for degradation products, particles and potency	High
Packaging and device engineering	Supports home administration and commercial scale-up	High

Commodity sodium chloride, phosphate and Water for Injection are unlikely to generate substantial standalone value. Their economic importance arises from pharmaceutical-grade qualification, lot consistency, supply continuity and compatibility with the drug substance and container closure system.

Polysorbate 20 is more commercially attractive because its quality can affect product stability and particulate control. Suppliers with well-characterized low-peroxide grades, trace-metal control and robust documentation have a stronger position than suppliers competing solely on price.

How does Amvuttra compare with other RNA medicines?

Amvuttra’s excipient strategy is closest to other GalNAc-conjugated RNA products, not to lipid nanoparticle products.

Product	Active technology	Delivery system	Typical formulation complexity	Dosing pattern
Amvuttra	Vutrisiran siRNA	GalNAc conjugate	Low-complexity aqueous solution	Every three months
Givlaari	Givosiran siRNA	GalNAc conjugate	Aqueous injectable formulation	Monthly
Oxlumo	Lumasiran siRNA	GalNAc conjugate	Aqueous injectable formulation	Loading and maintenance dosing
Leqvio	Inclisiran siRNA	GalNAc conjugate	Aqueous injectable formulation	Initial, three-month, then six-month dosing
Onpattro	Patisiran siRNA	Lipid nanoparticle	Multi-component lipid formulation	Intravenous, every three weeks
Wainua	Eplontersen antisense oligonucleotide	Ligand-conjugated antisense platform	Aqueous injectable formulation	Monthly
Tegsedi	Inotersen antisense oligonucleotide	Unconjugated antisense	Aqueous injectable formulation	Weekly

The comparison matters commercially. GalNAc products reduce the need for complex nanoparticle excipient systems and support subcutaneous dosing. Their competitive differentiation comes from sequence design, ligand conjugation, potency, durability, safety, device usability and manufacturing control.

Amvuttra’s quarterly dosing provides a stronger commercial proposition than monthly or weekly injectable RNA products. The excipient system supports that proposition indirectly by enabling a concentrated, low-volume product suitable for self-administration or administration by a health-care professional.

What formulation patents protect Amvuttra?

Amvuttra’s core intellectual-property position is likely broader than its disclosed excipients. The principal barriers generally include:

1. The vutrisiran siRNA sequence and target transthyretin biology.
2. GalNAc conjugation chemistry and ligand architecture.
3. Oligonucleotide backbone and sugar modifications.
4. Methods of treating hereditary transthyretin-mediated amyloidosis.
5. Dosing regimens and patient-selection methods.
6. Manufacturing processes for the conjugated siRNA.
7. Liquid formulation and stability claims.
8. Prefilled-syringe and delivery-system claims.
9. Crystalline, impurity or process-specific forms where applicable.

The disclosed excipients themselves are established pharmaceutical ingredients and are unlikely to provide the principal exclusivity barrier. A formulation patent could still protect a defined combination of vutrisiran, buffer, surfactant, tonicity agent, concentration range, pH range, degradation profile or container closure. Such claims are commercially relevant if they cover the marketed product and are listed or asserted against a competing applicant.

Patent analysis must distinguish between composition-of-matter protection, formulation protection and method-of-use protection. A competitor may avoid a formulation claim by changing the surfactant, buffer or device while remaining exposed to sequence, conjugate or treatment-method claims.

What is the FDA regulatory status of Amvuttra?

The FDA approved Amvuttra in June 2022 for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. The product is approved under NDA 214697. (FDA, 2022; FDA, 2024a)

Amvuttra is a chemically synthesized oligonucleotide drug rather than a monoclonal antibody or other protein biologic. Conventional biosimilar analysis therefore does not apply in the same way as it does to products licensed under the Public Health Service Act. A future competitor would more likely pursue an abbreviated or hybrid small-molecule pathway, depending on FDA classification, product-specific requirements and the scope of the reference product’s patents and exclusivities.

Orange Book considerations

Amvuttra is an FDA-approved prescription drug with an NDA. The commercial relevance of Orange Book data depends on:

• Whether patents covering the approved product or use are listed.
• Whether the listed patents cover the drug substance, formulation, method of use or device.
• Whether a future applicant can certify to those patents.
• Whether the applicant files a Paragraph IV certification.
• Whether the patent holder brings suit within the statutory litigation window.

The Orange Book position should be evaluated against the current FDA listing and the latest NDA labeling. Patent expiry dates cannot be inferred reliably from the product label alone because patent term adjustment, patent term extension, terminal disclaimers and pediatric exclusivity can change the effective date.

When does Amvuttra lose exclusivity?

Amvuttra’s commercial exclusivity has several components rather than one universal expiry date.

Exclusivity or barrier	Commercial effect
FDA regulatory exclusivity	Delays certain abbreviated applications for the statutory period
Patent protection	Can block approval or launch if valid and infringed
Pediatric exclusivity	Can add six months when granted
Orphan-drug exclusivity	May restrict approval of the same drug for the same disease or condition
Sequence and conjugate patents	Can prevent practical design-around
Method-of-use patents	May limit approved indications or labeled uses
Formulation and device patents	May narrow substitutable products or extend lifecycle protection
Manufacturing know-how	Can delay scale-up even after formal patent expiry

Amvuttra received orphan-drug designation for hereditary transthyretin-mediated amyloidosis, making orphan-drug exclusivity an important regulatory consideration for the approved orphan indication. Orphan exclusivity does not block every competing product. Its effect depends on the sameness of the drug, the disease or condition, and the regulatory pathway. (FDA, 2024b)

A competitor may still launch through a different indication, a different molecular construct or a distinct regulatory theory if it avoids the relevant exclusivity and patent barriers.

Which companies could challenge Amvuttra?

Potential competitive pressure comes from several categories rather than from conventional generic manufacturers alone.

Direct RNA competitors

Alnylam’s own products, including Onpattro and other transthyretin-directed programs, create internal competition across delivery platforms. Ionis Pharmaceuticals and AstraZeneca’s Wainua provide an antisense alternative for transthyretin amyloidosis. Pfizer’s Vyndaqel and Vyndamax stabilize transthyretin rather than silence its production.

Follow-on siRNA developers

Companies with GalNAc-siRNA platforms could develop a competing transthyretin product. The principal technical challenges include:

• Achieving durable transthyretin suppression.
• Matching or improving quarterly dosing.
• Demonstrating clinical benefit in neuropathy or cardiomyopathy.
• Producing a stable, low-volume injectable formulation.
• Establishing a competitive safety profile.
• Avoiding Alnylam’s sequence, conjugate and method patents.

Generic or hybrid applicants

A generic-style entrant would face more than an excipient substitution problem. It would need to address analytical comparability for a complex siRNA conjugate, including identity, sequence integrity, conjugation ratio, impurity profile, potency, aggregation and product-related variants. Small changes in excipient composition could affect syringe adsorption, subvisible particles, potency and stability.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV challenge would be commercially significant only if the applicant could support a credible noninfringement or invalidity position against the relevant listed patents. The likely dispute areas are:

• Whether the proposed product uses the claimed vutrisiran sequence.
• Whether the proposed GalNAc ligand and conjugation chemistry fall within asserted claims.
• Whether the formulation uses the claimed pH, surfactant, concentration or stability ranges.
• Whether the proposed label induces infringement of a method-of-use patent.
• Whether manufacturing steps practice process claims.
• Whether a device or prefilled syringe is included in the listed patent estate.

For a complex oligonucleotide, litigation risk can arise before commercial launch because manufacturing and analytical processes may expose process-patent issues. A competitor could also pursue a declaratory judgment, inter partes review or a negotiated license rather than wait for an ANDA-based dispute.

No broad public conclusion should be drawn from the absence of a high-profile Paragraph IV case. RNA products often have smaller potential entrant pools than conventional oral drugs, and technical manufacturing barriers can reduce the incentive to challenge patents.

How strong is the Amvuttra patent estate?

The estate is commercially strong where it combines multiple layers of protection:

• A clinically validated transthyretin target.
• A specific siRNA sequence.
• GalNAc delivery chemistry.
• Durable quarterly dosing.
• A commercial prefilled-syringe product.
• Manufacturing know-how for a conjugated oligonucleotide.
• Orphan-drug and regulatory exclusivity.

The formulation layer is probably a supporting component rather than the sole barrier. A simple excipient composition is easier to design around than a proprietary sequence or conjugation architecture. The strongest practical protection therefore comes from the combined sequence-conjugate-product system.

Patent strength should be assessed claim by claim. Key indicators include independent-claim breadth, written-description support, prosecution amendments, continuation activity, terminal disclaimers, patent-term adjustment, Orange Book listing status and the availability of noninfringing alternative sequences or ligands.

What licensing opportunities exist around Amvuttra?

Licensing opportunities are more likely around platform technology and commercial infrastructure than around the disclosed excipients.

Potential transaction areas include:

• GalNAc-siRNA delivery technology.
• Transthyretin-targeted sequences or backup sequences.
• Conjugation chemistry and linker systems.
• Sterile fill-finish capacity.
• Prefilled-syringe systems.
• Low-temperature logistics.
• Analytical methods for oligonucleotide identity and potency.
• Regional commercialization rights.
• Follow-on products for ATTR cardiomyopathy or related diseases.

Alnylam’s historical licensing model demonstrates the value of platform transactions involving RNA interference technology. The commercial terms for any particular collaboration must be evaluated from the underlying agreement, including territory, field, royalties, milestones, sublicensing rights and retained manufacturing rights. (Alnylam Pharmaceuticals, 2024b)

Excipient suppliers generally have limited leverage unless they provide a qualified grade, proprietary stabilization package, validated analytical method or supply agreement that is difficult to replace.

What manufacturing and IP barriers affect commercial entry?

Manufacturing is a major barrier to follow-on entry. A competing manufacturer must control:

• Oligonucleotide synthesis and purification.
• GalNAc conjugation.
• Residual reagent and solvent clearance.
• Duplex formation and strand integrity.
• Sterile filtration and low-volume filling.
• Particulate and endotoxin control.
• Prefilled-syringe assembly.
• Stability under refrigerated storage.
• Shipping and temperature-excursion performance.

The finished product’s apparent formulation simplicity does not eliminate process complexity. For oligonucleotides, the impurity profile and conjugation consistency can be as commercially important as the named excipients.

Geographic barriers also matter. FDA approval does not establish approval in Europe, Japan, China or other jurisdictions. Each region may apply different requirements to oligonucleotide characterization, device combination products, manufacturing sites, data exclusivity and patent enforcement.

What generic launch scenarios are plausible?

Three launch scenarios are commercially relevant.

Early authorized or licensed competition

A licensed competitor could enter with access to Alnylam technology, manufacturing know-how or a settlement agreement. This is the lowest-risk route but would likely involve royalties, field restrictions or delayed entry.

Post-patent follow-on product

A manufacturer could launch after relevant composition, formulation, method and regulatory barriers expire. This approach avoids litigation risk but requires a fully developed oligonucleotide manufacturing platform.

Litigation-driven Paragraph IV entry

A challenger could seek approval before patent expiry by asserting invalidity, noninfringement or a design-around. This route has the highest legal and technical risk. A successful challenge could produce substantial value because quarterly dosing and specialty pricing can support meaningful revenue before broader competition emerges.

What revenue exposure does Amvuttra create?

Amvuttra’s revenue exposure is tied to a high-value rare-disease market, quarterly dosing and expansion of transthyretin amyloidosis treatment. The main commercial variables are:

• Number of diagnosed hereditary ATTR patients.
• Uptake among patients previously treated with tafamidis, patisiran or inotersen.
• Use in polyneuropathy and any approved cardiomyopathy indication.
• Reimbursement and prior authorization.
• Geographic expansion.
• Persistence on quarterly dosing.
• Competition from antisense and transthyretin stabilizer products.
• Timing of follow-on entry.

For suppliers, the opportunity is proportional to manufacturing scale rather than excipient volume. A 0.5 mL dose contains small quantities of commodity excipients, so the largest addressable value lies in qualified supply, testing, fill-finish and device services.

Key Takeaways

• Amvuttra uses a simple, preservative-free aqueous formulation containing sodium phosphate dibasic, sodium chloride, polysorbate 20 and Water for Injection.
• The product’s commercial differentiation comes from GalNAc-siRNA delivery and quarterly subcutaneous dosing, not excipient novelty.
• Polysorbate 20 quality, container compatibility, oxidation control and particulate testing are the most relevant excipient opportunities.
• The main entry barriers are the siRNA sequence, GalNAc conjugate, manufacturing process, method of use and regulatory exclusivity.
• Conventional biosimilar substitution is not the primary competitive model for Amvuttra.
• Follow-on entrants would need specialized oligonucleotide manufacturing and analytical capabilities.
• The strongest commercial opportunities are in qualified excipient supply, sterile fill-finish, prefilled syringes, cold-chain logistics and RNA formulation services.
• Patent and Orange Book analysis must use current FDA records and the complete issued and pending patent family, not the package insert alone.

FAQs About Amvuttra Excipient and Commercial Strategy

Is Amvuttra a lipid nanoparticle formulation?

No. Amvuttra is a GalNAc-conjugated siRNA product formulated as an aqueous solution. It does not use the multi-lipid nanoparticle system associated with Onpattro.

Does Amvuttra contain polysorbate 80?

No. The FDA labeling identifies polysorbate 20, not polysorbate 80, as the surfactant excipient.

Can a competitor replace polysorbate 20 in a follow-on product?

Potentially, but changing the surfactant could affect stability, adsorption, particles, syringe compatibility and comparability. It could also create a different formulation profile that must satisfy FDA quality and clinical requirements.

Does Amvuttra require biosimilar approval?

Not in the conventional monoclonal-antibody sense. Vutrisiran is a chemically synthesized siRNA drug, so a follow-on applicant would need to follow the FDA pathway applicable to the product and demonstrate the required quality, safety and efficacy relationship.

Which Amvuttra component has the highest commercial IP value?

The sequence and GalNAc-conjugate architecture are likely more valuable than the disclosed excipients. The formulation and device patents can still add meaningful lifecycle protection when they cover the marketed presentation or restrict practical design-arounds.

References

1. Alnylam Pharmaceuticals, Inc. (2024a). Amvuttra (vutrisiran) injection, prescribing information.
2. Alnylam Pharmaceuticals, Inc. (2024b). 2023 annual report.
3. Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., Taneja, N., O’Shea, J., Shaikh, S., Yucius, K., Bettencourt, B. R., Charisse, N., Kumar, V., Schwartz, M. S., Mhatre, A., ... Manoharan, M. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and achieves robust RNAi-mediated gene silencing. Journal of the American Chemical Society, 136(49), 16958-16961.
4. U.S. Food and Drug Administration. (2022). FDA approves first-of-its-kind targeted RNAi treatment for hereditary transthyretin-mediated amyloidosis.
5. U.S. Food and Drug Administration. (2024a). Drugs@FDA: Amvuttra, NDA 214697.
6. U.S. Food and Drug Administration. (2024b). Orphan drug designation and exclusivity provisions.